These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 17674311)

  • 101. Prospects for the clinical management of human cytomegalovirus infections.
    Farrar GH; Bull JR; Greenaway PJ
    Vaccine; 1986 Dec; 4(4):217-24. PubMed ID: 3026105
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Live cytomegalovirus vaccination of renal transplant candidates. A preliminary trial.
    Glazer JP; Friedman HM; Grossman RA; Starr SE; Barker CF; Perloff LJ; Huang ES; Plotkin SA
    Ann Intern Med; 1979 Nov; 91(5):676-83. PubMed ID: 227299
    [TBL] [Abstract][Full Text] [Related]  

  • 103. First-line Therapy With Donor-derived Human Cytomegalovirus (HCMV)-specific T Cells Reduces Persistent HCMV Infection by Promoting Antiviral Immunity After Allogenic Stem Cell Transplantation.
    Zhao XY; Pei XY; Chang YJ; Yu XX; Xu LP; Wang Y; Zhang XH; Liu KY; Huang XJ
    Clin Infect Dis; 2020 Mar; 70(7):1429-1437. PubMed ID: 31067570
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Adoptive Transfer of Herpesvirusspecific Cytotoxic T Lymphocytes in Transplant Recipients.
    Comoli P; Maccario R; Locatelli F; Grossi P; Baldanti F; Revello MG; Gerna G
    Herpes; 2000 Feb; 7(1):9-12. PubMed ID: 11866994
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Is there a link between cytomegalovirus infection and new-onset posttransplantation diabetes mellitus? Potential mechanisms of virus induced beta-cell damage.
    Hjelmesaeth J; Müller F; Jenssen T; Rollag H; Sagedal S; Hartmann A
    Nephrol Dial Transplant; 2005 Nov; 20(11):2311-5. PubMed ID: 16046502
    [No Abstract]   [Full Text] [Related]  

  • 106. Differential outcome of neurological HCMV infection in two hematopoietic stem cell transplant recipients.
    Colombo AA; Giorgiani G; Rognoni V; Villani P; Furione M; Bonora MR; Alessandrino EP; Zecca M; Baldanti F
    BMC Infect Dis; 2012 Oct; 12():238. PubMed ID: 23031364
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Comparative virulence and immunogenicity of the Towne strain and a nonattenuated strain of cytomegalovirus.
    Quinnan GV; Delery M; Rook AH; Frederick WR; Epstein JS; Manischewitz JF; Jackson L; Ramsey KM; Mittal K; Plotkin SA
    Ann Intern Med; 1984 Oct; 101(4):478-83. PubMed ID: 6089634
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Vaccination against cytomegalovirus, the changeling demon.
    Plotkin SA
    Pediatr Infect Dis J; 1999 Apr; 18(4):313-25; quiz 326. PubMed ID: 10223683
    [No Abstract]   [Full Text] [Related]  

  • 109. Burden of disease associated with human cytomegalovirus and prospects for elimination by universal immunisation.
    Griffiths PD
    Lancet Infect Dis; 2012 Oct; 12(10):790-8. PubMed ID: 23017365
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Vaccination after stem cell transplant: a review of recent developments and implications for current practice.
    Wilck MB; Baden LR
    Curr Opin Infect Dis; 2008 Aug; 21(4):399-408. PubMed ID: 18594293
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Cytomegalovirus vaccine in renal allograft recipients.
    Marker SC; Simmons RL; Balfour HH
    Transplant Proc; 1981 Mar; 13(1 Pt 1):117-9. PubMed ID: 6267748
    [No Abstract]   [Full Text] [Related]  

  • 112. Cellular therapy with sequential unmanipulated donor lymphocyte infusions in drug-resistant cytomegalovirus (CMV) encephalitis.
    Akpek G; Mikulski M; Kleinberg M; Badros A; Yanovich S; Rapoport AP
    Blood; 2011 May; 117(21):5772-4. PubMed ID: 21617009
    [No Abstract]   [Full Text] [Related]  

  • 113. CVM: pathogenesis and prevention of human infection. International workshop held April 20-22, 1983 at the Children's Hospital of Philadelphia, PA.
    Birth Defects Orig Artic Ser; 1984; 20(1):1-515. PubMed ID: 6329355
    [No Abstract]   [Full Text] [Related]  

  • 114. The launching of a cytomegalovirus vaccine.
    Hanshaw JB
    Am J Dis Child; 1982 Apr; 136(4):291-2. PubMed ID: 6280489
    [No Abstract]   [Full Text] [Related]  

  • 115. Letter: Vaccination against cytomegalovirus?
    Pagano JS; Huang ES
    Lancet; 1974 Feb; 1(7852):316-7. PubMed ID: 4130502
    [No Abstract]   [Full Text] [Related]  

  • 116. Cytomegalovirus (AD169) infection in human chondrocyte cell cultures.
    Patti AM; Vulcano A; Gabriele A; Della Rocca C
    Ann Ig; 2007; 19(3):177-80. PubMed ID: 17658104
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Vaccines against human cytomegalovirus: time to test.
    Britt WJ
    Trends Microbiol; 1996 Jan; 4(1):34-8. PubMed ID: 8824793
    [TBL] [Abstract][Full Text] [Related]  

  • 118. T-lymphocyte subsets and proliferative responses following immunization with cytomegalovirus vaccine.
    Carney WP; Hirsch MS; Iacoviello VR; Starr SE; Fleisher G; Plotkin SA
    J Infect Dis; 1983 May; 147(5):958. PubMed ID: 6302180
    [No Abstract]   [Full Text] [Related]  

  • 119. Cytomegalovirus vaccine live (Pasteur Mérieux Connaught).
    Drugs R D; 1999 Nov; 2(5):310-2. PubMed ID: 10728468
    [No Abstract]   [Full Text] [Related]  

  • 120. Reanalysis of TransVax immunogenicity.
    Kharfan-Dabaja MA; Boeckh M; Wilck MB; Langston AA; Chu AH; Wloch MK; Smith LR; Rolland AP; Kenney RT
    Lancet Infect Dis; 2013 Jan; 13(1):18. PubMed ID: 23257230
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.